Aims. Unicompartmental knee arthroplasty (UKA) provides improved early functional outcomes and less postoperative morbidity and pain compared with total knee arthroplasty (TKA). Opioid prescribing has increased in the last two decades, and recently states in the USA have developed online Prescription Drug Monitoring Programs to prevent overprescribing of controlled substances. This study evaluates differences in opioid requirements between patients undergoing TKA and UKA. Patients and Methods. We retrospectively reviewed 676 consecutive TKAs and 241 UKAs. Opioid prescriptions in morphine milligram equivalents (MMEs), sedatives, benzodiazepines, and stimulants were collected from State Controlled Substance Monitoring websites six months before and nine months after the initial procedures. Bivariate and multivariate analysis were performed for patients who had a second prescription and continued use. Results. Patients undergoing UKA had a second opioid prescription filled 50.2% of the time, compared with 60.5% for TKA (p = 0.006). After controlling for potential confounders, patients undergoing UKA were still less likely to require a second prescription than those undergoing TKA (adjusted odds ratio (OR) 0.58, 95% confidence interval (CI) 0.42 to 0.81; p = 0.001). Continued opioid use requiring more than five prescriptions occurred in 13.7% of those undergoing TKA and 5.8% for those undergoing UKA (p = 0.001), and was also reduced in UKA patients compared with TKA patients (adjusted OR 0.33, 95% CI 0.16 to 0.67; p = 0.022) in multivariate analysis. The continued use of opioids after six months was 11.8% in those undergoing TKA and 8.3% in those undergoing UKA (p = 0.149). The multivariate models for second prescriptions, continued use with more than five, and continued use beyond six months yielded concordance scores of 0.70, 0.86, and 0.83, respectively. Conclusion. Compared with TKA, patients undergoing UKA are less likely to require a second opioid prescription and use significantly fewer opioid prescriptions. Thus, orthopaedic surgeons should adjust their patterns of prescription and educate patients about the reduced expected analgesic requirements after UKA compared with TKA. Cite this article: Bone Joint J 2019;101-B(7 Supple C):22–27

Aims. The aim of this study was to determine the general postoperative opioid consumption and rate of appropriate disposal of excess opioid prescriptions in patients undergoing primary unilateral total knee arthroplasty (TKA). Patients and Methods. In total, 112 patients undergoing surgery with one of eight arthroplasty surgeons at a single specialty hospital were prospectively enrolled. Three patients were excluded for undergoing secondary procedures within six weeks. Daily pain levels and opioid consumption, quantity, and disposal patterns for leftover medications were collected for six weeks following surgery using a text-messaging platform. Results. Overall, 103 of 109 patients (94.5%) completed the daily short message service (SMS) surveys. The mean oral morphine equivalents (OME) consumed during the six weeks post-surgery were 639.6 mg (. sd. 323.7; 20 to 1616) corresponding to 85.3 tablets of 5 mg oxycodone per patient. A total of 66 patients (64.1%) had stopped taking opioids within six weeks of surgery and had the mean equivalent of 18 oxycodone 5 mg tablets remaining. Only 17 patients (25.7%) appropriately disposed of leftover medications. Conclusion. These prospectively collected data provide a benchmark for general opioid consumption after uncomplicated primary unilateral TKA. Many patients are prescribed more opioids than they require, and leftover medication is infrequently disposed of appropriately, which increases the risk for illicit diversion. Cite this article: Bone Joint J 2019;101-B(7 Supple C):98–103

Introduction. The prescription of opioids has increased in the last two decades. Recently, several states have developed online Prescription Drug Monitoring Programs aimed at preventing overprescribing of controlled substances. Unicompartmental knee arthroplasty (UKA) has been shown to provide improved early functional outcomes, faster recovery, and less postoperative morbidity and pain than total knee arthroplasty (TKA). The aim of this study is to evaluate differences in opioid prescription requirements between patients undergoing TKA and UKA. Methods. We retrospectively reviewed consecutive series of primary TKA from January 2017 to July 2017 and primary UKA from January 2016 to July 2017 using standardized perioperative pain protocols. All patients that underwent any other procedure 6 months prior to and after index surgery were excluded, resulting in 740 TKA and 241 UKA. Demographic and comorbidity information was collected for all patients. Opioid prescriptions, morphine milligram equivalents (MME), sedatives, benzodiazepines, and stimulants were collected from State Controlled Substance Monitoring website 6 months prior and after index procedures. Univariate and multivariate analysis were performed for patients that had a second prescription and continued use (defined as more than 6 months postoperatively). Results. Patients undergoing UKA had a second opioid prescription filled 50.2% of the time compared to 60.5% for TKA (p=0.006). In addition, continued opioid use after 6 months was 8.3% in UKAs compared to 11.8% in TKAs (p=0.149). When controlling for potential confounders, patients undergoing UKA were less likely to require a second prescription than TKA patients (adjusted odds ratio: 0.603 (95% Confidence Interval (CI): 0.425–0.855). In addition, continued use of opioids after 6 months was also reduced compared to patients undergoing TKA (adjusted OR: 0.51, 95% CI: 0.27–0.97) in the multivariate analysis. Other independent predictors of continued opioid use include obesity (OR 1.79, 95% CI 1.07–3.00) and preoperative opioid use (OR 1.66 per script, 95% CI: 1.49–1.86). Our models for second script and continued use reported AUC scores of 0.65 and 0.85, respectively. Conclusion. Patients with UKA are less likely to require a second opioid prescription and have continued opioid use even when controlling for a variety of potential confounders. Given the reduced opioid requirements associated with UKA, this study supports that orthopaedic surgeons should adjust their prescription patterns and educate patients regarding expected analgesic needs. Due to the retrospective nature of this study we were unable to precisely quantify the amount of opioids consumed in these patient groups. An ongoing prospective study will more accurately determine the duration and quantity of opioid use after UKA compared to TKA

Aims. Robotic-assisted total knee arthroplasty (RA-TKA) has been introduced to provide accurate bone cuts and help achieve the target knee alignment, along with symmetric gap balancing. The purpose of this study was to determine if any early clinical benefits could be realized following TKA using robotic-assisted technology. Methods. In all, 140 consecutive patients undergoing RA-TKA and 127 consecutive patients undergoing conventional TKA with minimum six-week follow-up were reviewed. Differences in visual analogue scores (VAS) for pain at rest and with activity, postoperative opiate usage, and length of stay (LOS) between the RA-TKA and conventional TKA groups were compared. Results. Patients undergoing RA-TKA had lower average VAS pain scores at rest (p = 0.001) and with activity (p = 0.03) at two weeks following the index procedure. At the six-week interval, the RA-TKA group had lower VAS pain scores with rest (p = 0.03) and with activity (p = 0.02), and required 3.2 mg less morphine equivalents per day relative to the conventional group (p < 0.001). At six weeks, a significantly greater number of patients in the RA-TKA group were free of opioid use compared to the conventional TKA group; 70.7% vs 57.0% (p = 0.02). Patients in the RA-TKA group had a shorter LOS; 1.9 days versus 2.3 days (p < 0.001), and also had a greater percentage of patient discharged on postoperative day one; 41.3% vs 20.5% (p < 0.001). Conclusion. Patients undergoing RA-TKA had lower pain levels at both rest and with activity, required less opioid medication, and had a shorter LOS

Introduction. Even as the outcomes of primary total knee arthroplasty (TKA) continue to improve, there remain increasing concerns about pain control after surgery and prolonged narcotic use. Cryoneurolysis has been demonstrated to reduce osteoarthritis knee pain for up to 90 days. We hypothesized that postoperative narcotic use could be reduced following preoperative cryoneurolysis of the superficial genicular nerves. Methods. Primary TKA patients were randomized into either a control or cryoneurolysis treatment group. Both followed the same preoperative, intraoperative, and postoperative pain management protocol, except the treatment group had cryoneurolysis of their superficial genicular nerves 3–7 days prior to surgery. All patients were prescribed 40 narcotic pills at discharge and pills were counted at 72 hours and at 2,6, and 12 weeks postoperatively. The primary endpoint was daily morphine equivalent (DME) based on pill count and secondary endpoints were changes in pain and Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, Jr.) scores. Results. Per-protocol results demonstrated that the DME for the treatment group was significantly lower at 72 hours (10.9 mg vs. 14.9 mg, p=0.0389), 6 weeks (4.2 mg vs. 5.9 mg, p=0.0186) and 12 weeks (2.4 mg vs 3.4 mg p=0.0234). Overall, there was a 29% reduction in the DMEs over the entire 12-week postoperative period. Only 14% of the treatment group consumed opioids past 6 weeks compared to 44% of the control group (p=0.0005). The treatment group demonstrated a greater reduction in pain scores from baseline at 72 hours and 12 weeks. The treatment group also showed significant improvements in KOOS Jr. scores compared to the control group at all timepoints. Conclusions. The results demonstrate that preoperative cryoneurolysis can reduce opioid consumption after TKA. The early cessation of opioid consumption is especially encouraging given the association of prolonged narcotic use with increased complications following surgery. Preoperative cryoneurolysis should be considered as part of a multimodal protocol to reduce opioid consumption and pain and improve function after TKA. For figures, tables, or references, please contact authors directly

Introduction. Opioid abuse is a national epidemic. Traditional pain management after total knee arthroplasty (TKA) relied heavily on opioids. The evidence that in-hospital multimodal pain management (MMPM) is more effective than opioid-only analgesia is overwhelming. There has been little focus on post-discharge pain management. The purpose of this study was to determine whether MMPM after TKA could reduce opioid consumption in the 30-day period after hospital discharge. Methods. This was a prospective, two-arm, comparative study with a provider cross-over design. The first arm utilized a standard opioid-only (OO) prn regimen. The second arm utilized a 30-day MMPM regimen (standing doses of acetaminophen, metaxalone, meloxicam, gabapentin) and opioid medications prn. Surgeons crossed over protocols every four weeks. The primary outcome measure was VAS pain score. Secondary outcome measures included morphine milligram equivalents (MME) consumed, failure of the protocol, and manipulation under anesthesia (MUA). A pre-hoc power analysis was performed for the primary outcome measure and an intent-to-treat analysis was done utilizing a longitudinal mixed model. Results. There were 43 patients in the OO cohort and 39 patients in the MMPM cohort. There was no difference in the baseline demographics or preoperative scores (p=0.94). There was no clinically meaningful difference in VAS score between the two groups at any time. The average opioid consumption at 30-days was 469 and 344 MME's for the OO and MMPM cohorts, respectively (p=0.026). 19/43 (44.2%) patients in the OO cohort failed vs. 4/39 (10.3%) in the MMPM cohort (p=0.002). There was 1 MUA in the OO and none in the MMPM cohort (p=0.338). Discussion. A 30-day post-discharge multimodal pain regimen reduced opioid use after TKA. Opioid-only regimens are at an increased risk of failure to control pain. As a result of this study, multimodal pain management after hospital discharge is standard at our institution

Introduction. Over the past few decades, opioid abuse has become a major threat to public health. In 2013 alone, enough opioid prescriptions were written in the United States for every American adult to have their own bottle of pills. Since then, opioid prescribing rates and opioid related deaths have continued to grow, with over 46 people dying on average each day from prescription opioid overdoses in 2016. Orthopaedic surgeons are among the top 5 specialties in the number of opioid prescriptions written. For many common surgeries, such as total knee arthroplasty (TKA), post-discharge prescriptions are based on prescriber habits and opinion. There exists limited data-driven protocols to guide post-operative opioid prescribing practices. The purpose of this prospective study was to determine the average postoperative opioid consumption in patients undergoing primary TKA using a novel mobile text messaging platform. We hypothesized that majority of patients undergoing TKA do not properly dispose of left over pills after surgery. Methods. 95 patients undergoing primary unilateral TKA with one of nine arthroplasty surgeons at a single orthopaedic specialty hospital were prospectively enrolled. Daily pain levels and opioid consumption, and quantity and disposal patterns for left over medications were collected for six weeks following surgery using a novel mobile phone text messaging system. This system automatically queried patients twice a day, storing responses on a secure third-party host that investigators monitored and used to generate data reports in real-time. Results. Of the 95 patients enrolled, 1 was excluded for undergoing a secondary procedure in the acute postoperative data collection period. Of the remaining 94 patients, 88 (93.6%) completed the daily SMS surveys and were included in analysis. Average age was 62.0 ± 7.1 years, BMI 31.1 ± 6.2, and length of hospital stay 2.6 ± 1.2 days. The average oral morphine equivalents (OME) consumed during the 6 weeks post-surgery were 617.3 ± 350.26 mg, which corresponds to a mean consumption of 82 oxycodone 5 mg tablets per patient. For the 55(58.5%) of patients who had stopped taking opioids within 6 weeks of surgery, there were on average 196.2 mg OME left over, the equivalent of 26 oxycodone 5 mg tablets; 20% of those who stopped taking opioids had at least 367.5 mg OME left over, the equivalent of at least 49 oxycodone 5 mg tablets. Only 26.5% of patients with left over pills described an appropriate method of disposal of left over medications, with most patients storing left over pills in their homes. Conclusion. This prospectively collected data provides a benchmark for average opioid consumption after uncomplicated primary unilateral TKA. Many patients are prescribed more opioids than they require, and left-over medication is infrequently disposed of appropriately, which increases the risk for illicit diversion. Prospective collection of patient reported opioid consumption has tremendous value in the development of national postoperative guideline protocols while informing further research and strategies aimed to reduce opioid use and misuse and in predicting patient characteristics associated with increased opioid consumption after surgery

Introduction. The use of intraoperative liposomal bupivacaine (LB) peri-articular injection has been highly debated for total knee arthroplasty (TKA). We evaluated the effect of an institutional-wide discontinuation of intraoperative LB on immediate postoperative pain scores, opioid consumption, and objective functional outcomes. Material and Methods. Between July 1, 2019 and November 30, 2019, an institutional policy discontinued use of intraoperative LB, while the volume of non-LB with epinephrine was increased from 40-ml to 60-ml. A historical cohort was derived from patients undergoing TKA between January 1, 2019 and June 30, 2019. All patients received the same opioid sparing protocol, minimizing variability in prescribing habits. No adductor canal blocks/pumps were utilized. Nursing documented verbal rating scale (VRS) pain scores were collected from our electronic data warehouse and averaged per patient per 12-hour interval. Opiate administration events were derived as Morphine Milligram Equivalences (MMEs) per patient per 24-hour interval. To assess immediate postoperative functional status, the validated Activity Measure for Post-Acute Care (AM-PAC) tool was utilized. All time events were calculated relative to TKA completion instant. Results. 789 primary TKAs did not receive intraoperative LB, while 888 patients acted as controls. Age was significantly greater in patients that did not receive intraoperative liposomal bupivacaine (66.80±8.97 vs 65.57±9.46; p<.01). Gender, BMI, ASA physical status score, race, smoking status, marital status, surgical time, length of stay and discharge disposition were similar between the two groups (p>.05). Compared to historical controls, discontinuation of LB demonstrated no significant difference in postoperative inpatient VRS pain scores up to 72 hours (p>.05), opioid administration up to 96 hours (p>.05), or AM-PAC scores within the first 24 hours (p>.05). Discussion. Subjective pain scores, opioid consumption, and functional scores were unchanged in the early postoperative period following the discontinuation of intraoperative liposomal delivery of bupivacaine in TKA

Introduction. Postoperative pain is a concern for patients undergoing Total Knee Arthroplasty (TKA) and plays an important role in opioid consumption, length of stay, and postoperative function. The purpose of this study was to compare outcomes in patients who underwent primary TKA comparing femoral and sciatic (F+S) combination motor nerve block versus an adductor canal and the interspace between the popliteal artery and the capsule of the posterior knee (ACB+IPACK) combination sensory nerve block. Methods. 100 consecutive primary TKA cases performed by a single surgeon using the same surgical approach and implant design were reviewed. The first 50 patients received F+S nerve blocks and the second 50 received ACB+IPACK blocks preoperatively. Both groups also received total intravenous anesthesia (TIVA). Differences in opioid requirements, length of stay (LOS), distance walked, Western Ontario & McMasters University Osteoarthritis Index (WOMAC), Knee Society (KSS) function scores, Visual Analog Scores (VAS) for pain at rest and with activity, and postoperative complications were analyzed. There were no differences in the groups with respect to age, sex or BMI. Results. 62% of patients were discharged on postoperative day #1 in the ACB+IPACK group compared to 14% in the F+S group (p<.0001). The ACB+IPACK patients had a shorter LOS (average 1.48 days versus 2.02 days, p<0.0001), ambulated further on postop day #0 (average 21.4 feet versus 5.3 feet, p<0.0001), required less narcotics the day after surgery (average 15.7 versus 24.0 morphine equivalents p<0.0001) and at 2 weeks postoperative (average 6.2 versus 9.3 morphine equivalents, p=0.025), and required less manipulations under anesthesia (1 versus 5, p=0.204). WOMAC, KSS, and VAS scores were not significantly different. Discussion. The use of combination adductor canal and IPACK sensory blocks demonstrated improved early ambulation with decreased opioid use, length of stay, and postoperative manipulations. This study suggests that the use of combination sensory adductor canal and IPACK nerve blocks are superior to motor nerve blocks in patients undergoing primary TKA

Summary. Despite adoption of robust clinical pathways, narcotic administration within the inpatient setting is highly variable and may benefit from the implementation of standardized multi-modal pain management protocols. Introduction. Total knee arthroplasty (TKA) candidates have historically received high doses of opioids within the perioperative period for the management of surgical pain. Healthcare systems have responded by improving opioid prescribing documentation and implementing narcotic-sparing pain protocols into TKA integrated care pathways (ICP). Despite these efforts, there are few technological platforms specifically designed to measure the narcotic burden immediately postoperatively. Here we present an early iteration of an inpatient narcotic administration-reporting tool, which normalizes patient narcotic consumption as an average daily morphine-milligram-equivalence (MME) per surgical encounter (MME/day/encounter) among total knee arthroplasty (TKA) recipients. This information may help orthopaedic surgeons visualize their individual granular inpatient narcotic prescribing habits individually and compared to other surgeons, while taking into consideration patient and procedure specific variables in order to optimize use and curtail unnecessary narcotic prescriptions. Material and Methods. A query of our electronic data warehouse, was performed for patients undergoing elective primary TKA between January 1, 2016 to April 30, 2017. Patients undergoing revision or bilateral procedures were excluded. Patient demographics, inpatient and surgical factors, and inpatient narcotic administration were retrieved. Narcotic type, route and dose were converted into average total Morphine Milligram Equivalents per patient for each post- operative day (figure 1). These MME/day/encounter values were subsequently used determine mean and variance of narcotics prescribed by individual surgeons. A secondary analysis of regional distribution of inpatient narcotic consumption was determined by patient's zip codes. Results. In total, 20 surgeons performed 3,666 primary TKAs. The institutional average narcotic dose administered for a single surgical encounter was 34.45±60.06 MME/day (Figure 1). Average surgeon narcotic prescribing ranged from 18.54 to 42.84 MME/day. Similarly, intra-surgeon variability of narcotic prescribing habits varied from ±20.23 to ±129.02 MME/day. Further visualization of patient breakdown did not demonstrate a trend towards increased narcotic administration or variability for surgeons when compared to race or insurance type. Discussion. Our results suggest that narcotic administration following primary TKA demonstrated a substantial degree of intra-institutional variability for individual surgeons despite the use of standardized clinical pathways. TKA candidates may benefit from the implementation of a more rigid standardization of multi-modal pain management protocols that can control pain while minimizing the narcotic burden. Studies designed to analyze the variability of narcotic use in the post-operative period and determine strategies to minimize inappropriate variation are needed. For any figures or tables, please contact authors directly

Aims. The purpose of this study was to evaluate trends in opioid use after unicompartmental knee arthroplasty (UKA), to identify predictors of prolonged use and to compare the rates of opioid use after UKA, total knee arthroplasty (TKA) and total hip arthroplasty (THA). Materials and Methods. We identified 4205 patients who had undergone UKA between 2007 and 2015 from the Humana Inc. administrative claims database. Post-operative opioid use for one year post-operatively was assessed using the rates of monthly repeat prescription. These were then compared between patients with and without a specific variable of interest and with those of patients who had undergone TKA and THA. Results. A total of 4205 UKA patients were analysed. Of these, 1362 patients (32.4%) were users of opioids. Pre-operative opioid use was the strongest predictor of prolonged opioid use after UKA. Opioid users were 1.4 (81.6% versus 57.7%), 3.7 (49.5% versus 13.3%) and 5.5 (35.8% versus 6.5%) times more likely to be taking opioids at one, two and three months post-operatively, respectively (p < 0.05 for all). Younger age and specific comorbidities such as anxiety/depression, smoking, back pain and substance abuse were found to significantly increase the rate of repeat prescription for opioids after UKA. Overall, UKA patients required significantly less opioid prescriptions than patients who had undergone THA and TKA. Conclusion. One-third of patients who undergo UKA are given opioids in the three months pre-operatively. Pre-operative opioid use is the best predictor of increased repeat prescriptions after UKA. However, other intrinsic patient characteristics are also predictive. Cite this article: Bone Joint J 2018;100-B(1 Supple A):62–7

Abstract. Introduction. Spinal local anaesthesia and opioids have long been used as peri-operative analgesia for patients undergoing arthroplasty procedures. However, intrathecal opioids are associated with numerous complications. ERAS. ®. society guidelines for elective knee replacement (2019) strongly discourage the use of spinal opioids. This study aims to report the impact of low-dose spinal and local infiltrative analgesia on patients undergoing elective knee replacement. Methodology. Retrospective cohort study of patients undergoing knee replacement under the ERAS protocol over 2 years, at a district general hospital under the care of a single surgeon. Results. A total of 80 knee replacements were included in the study (M38:F42, mean age=72.7, mean BMI=31, ASA: 1=8, 2=54, 3=18). 91% received neuroaxial anaesthesia, 89% without intrathecal opioids. Local infiltrative analgesia was used in 99% of patients. The mean length of stay was significantly shorter (2 days), when compared to patients undergoing elective knee replacements without adherence to ERAS. ®. guidance (3.8 days), P<0.001. The average maximum pain score in PACU was 0.8 (0=no pain, 10=maximum pain). All patients were mobilised within 24 hours of surgery. No patients were readmitted within 30 days. 2 patients returned to theatre (retained surgical clip and MUA for stiffness). Conclusions. The implementation of ERAS. ®. guidelines has demonstrated significantly reduced admission days following elective knee arthroplasty. Combined with low complication rates, the reduction in admission days may result in increased hospital bed availability. This has the potential to positively impact elective arthroplasty waiting lists. Further research is underway to evaluate patient-reported outcome measures in this group

Abstract. Introduction. To compare the efficacy of adductor canal blocks (ACB) and periarticular anesthetic injections (PAI) with bupivacaine in total knee arthroplasty. Methods. 90 patients undergoing primary total knee arthroplasty under spinal anesthesia were randomized to 1 of 3 groups: ACB alone (15 mL of 0.5% bupivacaine), PAI alone (50 mL of 0.25% bupivacaine with epinephrine) and ACB + PAI. Primary outcome in this study was the visual analog scale (VAS) pain score in the immediate postoperative period. Secondary outcomes included postoperative opioid use, activity level during physiotheraphy, length of hospital stay and ROM. Results. Mean VAS pain score was significantly higher with ACB alone, compared with the score after use of ACB+PAI, on POD1 and POD3. Total opioid consumption through POD3 was significantly higher when ACB alone had been used compared with PAI alone and ACB+PAI. Opioid consumption in the ACB-alone group was significantly higher than that in the ACB + PAI group on POD2 and POD3 and significantly higher than that in the PAI alone group on POD2. There was no significant difference in opioid consumption between the patients treated with PAI alone and those who received ACB + PAI. The activity level during physiotherapy on POD0 was significantly lower after use of ACB alone than after use of PAI alone or ACB + PAI. Conclusion. Higher pain scores after total knee arthroplasty done with an ACB and without PAI, suggesting that ACB alone is inferior for perioperative pain control. There were no significant differences between ACB alone, PAI alone and ACB + PAI inparameters measured

Aims. Liposomal bupivacaine (LB) as part of a periarticular injection protocol continues to be a highly debated topic in total knee arthroplasty (TKA). We evaluated the effect of discontinuing the use of LB in a periarticular protocol on immediate postoperative pain scores, opioid consumption, and objective functional outcomes. Methods. On 1 July 2019, we discontinued the use of intraoperative LB as part of a periarticular injection protocol. A consecutive group of patients who received LB as part of the protocol (Protocol 1) and a subsequent group who did not (Protocol 2) were compared. All patients received the same opioid-sparing protocol. Verbal rating scale (VRS) pain scores were collected from our electronic data warehouse and averaged per patient per 12-hour interval. Events relating to the opiate administration were derived as morphine milligram equivalences (MMEs) per patient per 24-hour interval. The Activity Measure for Post-Acute Care (AM-PAC) tool was used to assess the immediate postoperative function. Results. A total of 888 patients received Protocol 1 and while 789 received Protocol 2. The mean age of the patients was significantly higher in those who did not receive LB (66.80 vs 65.57 years, p = 0.006). The sex, BMI, American Society of Anesthesiologists physical status score, race, smoking status, marital status, operating time, length of stay, and discharge disposition were similar in the two groups. Compared with the LB group, discontinuing LB showed no significant difference in postoperative VRS pain scores up to 72 hours (p > 0.05), opioid administration up to 96 hours (p > 0.05), or AM-PAC scores within the first 24 hours (p > 0.05). Conclusion. The control of pain after TKA with a multimodal management protocol is not improved by the addition of LB compared with traditional bupivacaine. Cite this article: Bone Joint J 2021;103-B(6 Supple A):102–107

Aims. Patient dissatisfaction following primary total knee arthroplasty (TKA) with manual jig-based instruments has been reported to be as high as 30%. Robotic-assisted total knee arthroplasty (RA-TKA) has been increasingly used in an effort to improve patient outcomes, however there is a paucity of literature examining patient satisfaction after RA-TKA. This study aims to identify the incidence of patients who were not satisfied following RA-TKA and to determine factors associated with higher levels of dissatisfaction. Methods. This was a retrospective review of 674 patients who underwent primary TKA between October 2016 and September 2020 with a minimum two-year follow-up. A five-point Likert satisfaction score was used to place patients into two groups: Group A were those who were very dissatisfied, dissatisfied, or neutral (Likert score 1 to 3) and Group B were those who were satisfied or very satisfied (Likert score 4 to 5). Patient demographic data, as well as preoperative and postoperative patient-reported outcome measures, were compared between groups. Results. Overall, 45 patients (6.7%) were in Group A and 629 (93.3%) were in Group B. Group A (vs Group B) had a higher proportion of male sex (p = 0.008), preoperative chronic opioid use (p < 0.001), preoperative psychotropic medication use (p = 0.01), prior anterior cruciate ligament (ACL) reconstruction (p < 0.001), and preoperative symptomatic lumbar spine disease (p = 0.004). Group A was also younger (p = 0.023). Multivariate analysis revealed preoperative opioid use (p = 0.012), prior ACL reconstruction (p = 0.038), male sex (p = 0.006), and preoperative psychotropic medication use (p = 0.001) as independent predictive factors of patient dissatisfaction. Conclusion. The use of RA-TKA demonstrated a high rate of patient satisfaction (629 of 674, 93.3%). Demographics for patients not satisfied following RA-TKA included: male sex, chronic opioid use, chronic psychotropic medication use, and prior ACL reconstruction. Patients in these groups should be identified preoperatively and educated on realistic expectations given their comorbid conditions. Cite this article: Bone Jt Open 2024;5(9):758–765

Abstract. Introduction. Adverse reactions to pain medication and pain can delay discharge after outpatient knee arthroplasty (TKA). Pharmacogenomics is an emerging tool that might help reduce adverse events by tailoring medication use based on known genetic variations in the CYP genes determining drug metabolism. This study was undertaken to evaluate whether pre-operative pharmacogenomic testing could optimize peri-operative pain management in patients undergoing total knee arthroplasty (TKA). Methods. This prospective, randomized study was performed in adults undergoing primary TKA. Patients in the experimental group underwent pre-operative pharmacogenomic evaluation and medication adjustments. Medications were not optimized for control patients. The Overall Benefit of Analgesic Score (OBAS) at 24 hours post-op was the primary outcome. Postoperative pain scores (VAS scale), total opioid use, time in recovery, and time to discharge were also compared. Results. 76 patients enrolled. 93% of patients had a poor-intermediate phenotype for at least one of four CYP genes. OBAS did not differ significantly between the two groups (4.2 control vs. 4.7 experimental; 95% CI −1.1 to 2.1) and was below the minimum clinically important difference of 2.0 points. Furthermore, there were no differences in any OBAS subscale including pain, satisfaction, or nausea. There were no differences in time in the recovery area or to discharge from hospital, or narcotic use. Conclusions. Despite many patients having a poor-intermediate phenotype for a CYP gene, pharmacogenomic testing prior to TKA and medication adjustment did not improve anesthesia or pain management outcomes, time to discharge or mean total opioid use after surgery

Aims. Adductor canal block (ACB) has emerged as an alternative to femoral nerve block (FNB) for analgesia after total knee arthroplasty (TKA). The optimal duration of maintenance of the ACB is still questionable. The purpose of this study was to compare the analgesic benefits and physiotherapy (PT) outcomes of single-shot ACB to two different regimens of infusion of the continuous ACB, 24-hour and 48-hour infusion. Patients and Methods. This was a prospective, randomized, unblinded study. A total of 159 American Society of Anesthesiologists (ASA) physical status I to III patients scheduled for primary TKA were randomized to one of three study groups. Three patients did not complete the study, leaving 156 patients for final analysis. Group A (n = 53) was the single-shot group (16 female patients and 37 male patients with a mean age of 63.9 years (. sd. 9.6)), group B (n = 51) was the 24-hour infusion group (22 female patients and 29 male patients with a mean age of 66.5 years (. sd. 8.5)), and group C (n = 52) was the 48-hour infusion group (18 female patients and 34 male patients with a mean age of 62.2 years (. sd. 8.7)). Pain scores, opioid requirements, PT test results, and patient-reported outcome instruments were compared between the three groups. Results. The proportion of patients reporting severe pain, defined as a pain score of between 7 and 10, on postoperative day number 2 (POD 2) were 21% for the single-shot group, 14% for the 24-hour block group, and 12% for the 48-hour block group (p = 0.05). Cumulative opioid requirements after 48 hours were similar between the groups. Functional outcomes were similar in all three groups in POD 1 and POD 2. Conclusion. There was no clear benefit of the 24-hour or 48-hour infusions over the single-shot ACB for the primary endpoint of the study. Otherwise, there were marginal benefits for keeping the indwelling catheter for 48 hours in terms of reducing the number of patients with moderate pain and improving the quality of pain management. However, all three groups had similar opioid usage, length of hospital stay, and functional outcomes. Further studies with larger sample sizes are needed to confirm these findings. Cite this article: Bone Joint J 2019;101-B:340–347

Introduction. There is little published evidence regarding cannabis or cannabinoid use among orthopedic patients, yet there is increasing public attention on its possible role in treating various medical conditions including pain. California passed legislation legalizing cannabis for medical treatment in 2003 and recreational use in 2018. All patients undergoing total joint arthroplasty (TJA) at our institution are screened preoperatively with a urine toxicology (UTox) screen. Though a positive test for other substances triggers surgery cancellation, a positive screen for cannabis and/or opiates does not impact whether surgery is performed. We sought to quantify the prevalence of cannabinoid and opioid use among patients with chronic pain from end-stage hip and knee osteoarthritis who underwent arthroplasty at our institution in 2012 and 2017. Methods. Institutional Review Board approval was obtained. A retrospective chart review was performed for all patients with severe arthritis who underwent total hip and knee arthroplasty (THA and TKA) at our institution during the calendar years 2012 and 2017. Patients were excluded if TJA was performed for acute trauma or if no pre-operative UTox screen was obtained. The UTox screen was used to determine preoperative cannabis and opioid use. Chi-squared testing was performed, and significance was defined as p<=0.05. Results. In the two years studied, 546 of 560 primary TJA surgeries (98%) had a pre-operative UTox screen performed. These 546 operations in 525 patients were reviewed (359 TKAs and 187 THAs). Comparing 2012 to 2017, the prevalence of preoperative cannabis use increased from 9% to 15% (p =.05) while the prevalence of opioid use decreased from 24% to 17% (p=.04). The proportion of patients who tested positive for both cannabis and opioids was low (3%) and did not change between 2012 and 2017 (p=.50). With the numbers available, patients who were using cannabis were no more or less likely to be taking opioids than non-cannabis users (p=.24). Discussion and Conclusion. To our knowledge, this is the first study to identify the prevalence and trends of cannabis use in patients undergoing TJA. At our institution, cannabis use increased more than 60% while opioid use decreased about 30% over a 5-year interval. Whether these findings are related remains unclear. Future directions will include studying postoperative opioid requirements, disposition, complications, and readmissions in TJA patients who use cannabis

Introduction. Controlling post-operative pain and reducing opioid requirements after total knee arthroplasty (TKA) remains a challenge, particularly in an era stressing rapid recovery protocols and early discharge. A single shot adductor canal block (ACB) has been shown to be effective in decreasing post-operative pain. This requires a specialty-trained Anesthesiologist skilled in ultrasound techniques, which imposes cost, time and skill barriers. Cadaveric studies and magnetic resonance imaging data have shown that access to the adductor canal is possible from within the joint, and thus the potential for intraoperative, intra-articular, surgeon administered ACB through a standard surgical approach is a feasible alternative to ultrasound guided ACB at the time of TKA. The purpose of the present study is to compare the efficacy of surgeon administered intraoperative ACB to anesthesiologist administered ACB. Methods. Patients' undergoing primary TKA were prospectively randomized to receive either an Anesthesiologist administered (Group 1) or Surgeon administered (Group 2) ACB using 15 ml of Ropivacaine 0.5%, both in conjunction with spinal anesthesia. Perioperative multimodal anesthesia was standardized for the two groups. Primary outcomes were pain visual analogue scale (VAS), range of motion, and opioid consumption. Secondary outcomes were patient satisfaction scores and length of stay (LOS). Results. 51 patients were enrolled and followed for a minimum of 6 weeks. 28 were randomized to Group 1 and 23 to Group 2. Opioid equivalents consumed were equal on POD 0,1, and 2 (p=0.86, 0.68, 0.47). Patients in Group 1 had significantly less pain on POD 0 [46.9 vs 61.8] (p=0.014), but there was no difference in pain on POD 1 or 2 (p=0.4, p=0.95). There was no difference in active flexion on post-operative day (POD) 0, POD 1 or 6 weeks post op (p=0.86, 0.074 and 0.59) and no difference in active extension on POD 0, 1, or 6 weeks (p=0.38,0.07and p=0.3). There was no difference in patient satisfaction with pain control on POD 0, 1, or 2 (p=0.6, p=0.7, p=0.9). There was no difference in LOS (1.3 vs 1.4 days p=0.34). Conclusion. Surgeon administered ACB is not inferior to Anesthesiologist administered ACB with respect to range of motion, patient satisfaction, or opioid consumption, although pain on the day of surgery may be greater. Surgeon administered ACB is an effective and cost- and time- efficient alternative to Anesthesiologist administered ACB. For figures, tables, or references, please contact authors directly

Aims. The purpose of this study was to use pharmacogenetics to determine the frequency of genetic variants in our total knee arthroplasty (TKA) patients that could affect postoperative pain medications. Pharmacogenetic testing evaluates patient DNA to determine if a drug is expected to have a normal clinical effect, heightened effect, or no effect at all on the patient. It also predicts whether patients are likely to experience side effects from medicine. We further sought to determine if changing the multimodal programme based on these results would improve pain control or reduce side effects. Methods. In this pilot study, buccal samples were collected from 31 primary TKA patients. Pharmacogenetics testing examined genetic variants in genes OPRM1, CYP1A2, CYP2B6, CYP2C19, CYP3A4, CYP2C9, and CYP2D6. These genes affect the pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs and opioids. We examined the frequency of genetic variants to any of the medications we prescribed including celecoxib, hydrocodone, and tramadol. Patients were randomized to one of two groups: the control group received the standard postoperative pain regimen, and the study group received a customized regimen based on the pharmacogenetic results. For the first ten postoperative days, patients recorded pain scores, medication, and side effects. Results. Genetic variants involving one or more medications in the multimodal pain protocol occurred in 13 of the 31 patients (42%). In total, eight patients (26%) had variants affecting more than one of the medications. For the 25 patients who recorded pain and medication logs, the mean pain levels and morphine equivalents (MEQs) consumed in the first ten days were higher in the control group than in the custom-guided group (p = 0.019 for pain and p = 0.655 for MEQ). Conclusion. Overall, 42% of patients had a variant involving one of the pain medications prescribed in our perioperative pain program for TKA. Ongoing research will help determine if using these data to modify a patient’s medication will improve outcomes. Cite this article: Bone Joint J 2020;102-B(6 Supple A):73–78